Ando Y, Fujita K, Sasaki Y, et al: UGT1AI* 6 and UGT1A1* 27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 2007; 9(3)258-262.
Van Cutsem E, Lang I, D’haens G, et al KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26: ASCO annual meeting,; abstr 2.